MedTrace Logo

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)

NCT05084911 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1807

Last updated 2023-06-18

No results posted yet for this study

Summary

This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase III clinical trial to evaluate efficacy and safety of pyramax in mild to moderate COVID-19 patients.

Conditions

Interventions

DRUG

Pyramax

Pyronaridine-Artesunate(180/60mg) tablet for 3days.

DRUG

Placebo

Placebo tablet for 3days.

Sponsors & Collaborators

  • Shin Poong Pharmaceutical Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-18
Primary Completion
2023-03-24
Completion
2023-03-24

Countries

  • Argentina
  • Chile
  • Colombia
  • Poland
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05084911 on ClinicalTrials.gov